Press Releases

Press Releases

November 25, 2024
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
November 12, 2024
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
November 4, 2024
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
November 1, 2024
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 23, 2024
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 9, 2024
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 4, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 6, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 26, 2024
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
August 12, 2024
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
Displaying 1 - 10 of 32